Can a single dose of an inhaled psychedelic lift depression that drugs have failed to treat?
Yes. In this trial, one dose of an inhaled psychedelic called GH001 put more than half of patients with hard-to-treat depression into remission within a week, while placebo helped no one. The treatment group dropped 15.2 points on a standard depression scale, a very large effect.
Treatment-resistant depression means standard antidepressants have not worked, often after several tries. It affects millions of people and can feel hopeless. So a single-day treatment that works this fast is a big deal, and that is exactly what researchers set out to test here.
What is GH001?
GH001 is an inhaled, short-acting form of a psychedelic compound called 5-MeO-DMT, also known as mebufotenin. Patients breathe it in during a single dosing day in a clinic. Because it acts and clears quickly, the experience is short. This is different from daily pills that you take for weeks or months before you know if they help.
What the data show
The results were striking. This phase 2b trial enrolled 81 adults with treatment-resistant depression. Each person received either GH001 or a placebo in a single dosing day. By day 8, the GH001 group improved 15.2 points on the MADRS, a widely used depression rating scale, while the placebo group showed essentially no change.
The size of that gap matters. The difference between the two groups had a Cohen’s d of about -2.0, which counts as a very large effect in medical research. Most depression treatments produce far smaller effects than this.
Remission was the most remarkable number. Among GH001 patients, 57.5 percent reached remission, meaning their depression symptoms had largely cleared. In the placebo group, that figure was 0 percent. The number needed to treat was 2, which means that for every two people treated with GH001, one extra person reached remission compared with placebo. That is an unusually strong result.
Dr. Kumar’s Take
I find this study really exciting, and I want to be careful at the same time. A single inhaled dose that pushes more than half of hard-to-treat patients into remission within a week is the kind of result we rarely see in psychiatry. The effect size and the number needed to treat of 2 are both remarkable.
That said, this is a phase 2b trial with 81 people and an early time point of day 8. We do not yet know how long the benefit lasts, how patients do after several months, or how it performs in larger and more diverse groups. Psychedelic treatments also need careful clinical settings and monitoring. I would not want anyone reading this to seek out 5-MeO-DMT on their own. The promise here is real, but it belongs in supervised trials for now.
How the study was done
This was a double-blind, randomized trial, which is the gold standard in medical research. Double-blind means neither the patients nor the clinicians knew who got the real drug and who got placebo, which helps prevent expectations from skewing the results. Randomized means people were assigned to each group by chance.
Patients received treatment on a single dosing day, and the main results were measured by day 8. Using placebo as the comparison makes the 0 percent remission rate in that group a useful benchmark for how powerful the GH001 effect really was.
Safety, limits, and caveats
On safety, the early picture looks reassuring. Side effects were mild to moderate and transient, meaning they passed quickly, and there were no serious adverse events reported. For a psychedelic given in a clinic, that is encouraging.
Still, the limits are important. The trial was small and followed patients only to an early time point, so durability is unknown. We cannot tell from this study whether the benefit holds at one month, six months, or a year. Larger trials with longer follow-up are the next step before this could become a real treatment option.
Practical Takeaways
- Do not try to obtain 5-MeO-DMT or any psychedelic on your own, since these results come from a controlled clinical trial with medical supervision, not at-home use.
- If you have depression that has not responded to standard medications, ask your psychiatrist about clinical trials of psychedelic-assisted treatments you might qualify for.
- Keep your expectations measured, because this is an early phase 2b study and longer, larger trials are still needed to confirm how lasting the benefit is.
Related Studies and Research
- Single-dose psilocybin vs placebo: first double-blind depression trial
- Single-dose psilocybin shows rapid, sustained antidepressant effects
- Normobaric oxygen treatment for mild-to-moderate depression: RCT
- Stanford neuromodulation therapy: double-blind RCT results
FAQs
How is GH001 different from regular antidepressants?
Standard antidepressants are pills you take daily, and they often take several weeks to show any benefit. GH001 is an inhaled psychedelic given in a single dosing day in a clinic, and the effect appeared within about a week in this trial. It also acts and clears from the body quickly, so the experience itself is short. This faster timeline is one of the main reasons researchers are interested in it.
Does a 57.5 percent remission rate mean it will work for most people?
It is a very promising number, but it comes from one phase 2b trial of 81 patients measured at day 8. A 57.5 percent remission rate compared with 0 percent on placebo is unusually strong, yet larger studies with longer follow-up are needed before we know how reliably it works across different patients. Remission in this trial was also measured at an early point, so we cannot say yet how many people stay well over months. Treat the result as encouraging early evidence, not a final answer.
Is inhaled 5-MeO-DMT safe?
In this trial, side effects were mild to moderate and passed quickly, and there were no serious adverse events. That is reassuring, but the study was small and short, so rare or longer-term risks may not show up yet. Psychedelics like this are given under medical supervision in a controlled setting for a reason. Using them outside of a clinic carries real risks and is not what this research supports.
Bottom Line
A single dose of the inhaled psychedelic GH001 produced a large and fast improvement in patients with treatment-resistant depression, with 57.5 percent reaching remission within a week compared with none on placebo. The effect size and number needed to treat of 2 are striking, and early safety looks good. This is one of the more promising depression results in recent years, but it is still an early trial that needs larger studies and longer follow-up before it can reach patients.
